Loading...
Market
Will ALIA-1758 enter Phase 2 trials by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries or AbbVie's official announcements
Story
AbbVie to Acquire J&J-Backed Aliada Therapeutics for $1.4 Billion in Alzheimer's Focus
Oct 28, 2024, 01:52 PM
AbbVie Inc. announced on Monday that it will acquire Aliada Therapeutics, a privately held therapy developer, for $1.4 billion in cash. The acquisition is aimed at strengthening AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. Aliada Therapeutics, a J&J-backed company, is known for its lead compound ALIA-1758 and its novel blood-brain barrier technology, which are expected to enhance AbbVie's capabilities in developing treatments for neurodegenerative diseases. This deal, involving a Phase 1 biotech, marks AbbVie's third acquisition of the year and underscores its commitment to expanding its research and development in the central nervous system (CNS) domain.
View original story
Similar markets
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Yes • 50%
No • 50%
